Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UroGen PharmaFRA:UR8 +1.22%60 Days Inventory is 409.71 as of Mar. 2026, which is 70% above its 10-year median of 240.50. GuruFocus rates FRA:UR8 with a GF Score™ of 60/100 and a GF Value™ of €17.88 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 638 Biotechnology companies, UroGen Pharma ranks worse than 69.44% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). UroGen Pharma's Average Total Inventories for the
three
months ended in Mar. 2026 was €16.1 Mil. UroGen Pharma's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €3.6 Mil.
Hence, UroGen Pharma's Days Inventory for the
three
months ended in Mar. 2026 was 409.71.
The historical rank and industry rank for UroGen Pharma's Days Inventory or its related term are showing as below:
FRA:UR8'
s Days Inventory Range Over the Past 10 Years
Min: 63.97 Med: 240.5 Max: 1368.75
Current: 309.51
During the past 11 years, UroGen Pharma's highest Days Inventory was 1368.75. The lowest was 63.97. And the median was 240.50.
FRA:UR8's Days Inventory is ranked worse than 69.44% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs FRA:UR8: 309.51
UroGen Pharma's Days Inventory
increased
from Mar. 2025 (335.21) to Mar. 2026 (409.71).
It might indicate that UroGen Pharma's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
UroGen Pharma's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.22.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
UroGen Pharma's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.36.
UroGen Pharma (FRA:UR8) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
UroGen Pharma's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
UroGen Pharma's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
UroGen Pharma Days Inventory Related Terms
UroGen Pharma Days Inventory Historical Data
* Premium members only.
The historical data trend for UroGen Pharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UR8 vs SEPN, FTRE, MLTX: Days Inventory Comparison
For the Biotechnology subindustry, UroGen Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma (FRA:UR8) has a Days Inventory of 409.71 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on UroGen Pharma and its competitors. This is 70% above median its historical median of 240.50. Over the past decade, UroGen Pharma's Days Inventory has ranged from 63.97 to 1,368.75. According to the industry distribution chart, UroGen Pharma ranks #443 out of 638 companies in the Biotechnology industry, placing it in the top 69.4%.
Is UroGen Pharma's Days Inventory too high?
UroGen Pharma's current Days Inventory of 409.71 is 70% above median its 10-year median of 240.50. Over the past 10 years, this metric has ranged from a low of 63.97 to a high of 1,368.75. The Biotechnology industry median Days Inventory is 183.20. UroGen Pharma's value of 409.71 is 123.6% above this industry median. Based on the distribution chart, UroGen Pharma ranks #443 out of 638 companies in the Biotechnology industry, which is below the industry midpoint. Overall, UroGen Pharma has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Days Inventory compare to SEPN and FTRE?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #443 out of 638 companies for Days Inventory. This places UroGen Pharma in the lower half of its industry. The industry median Days Inventory is 183.20. UroGen Pharma's value of 409.71 is 123.6% above this benchmark. Historically, UroGen Pharma's own Days Inventory has ranged from 63.97 to 1,368.75 over the past decade. While the company's 10-year median is 240.50 vs. the industry median of 183.20, UroGen Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UroGen Pharma's current Days Inventory of 409.71 is 123.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on UroGen Pharma and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UroGen Pharma's current Days Inventory is 409.71, which is 70% above median its own 10-year median of 240.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.88, compared to a current price of €33.93 — trading 89.8% above its estimated fair value. The current Days Inventory is 409.71, which is 70% above median its 10-year median of 240.50 and 123.6% above the Biotechnology industry median of 183.20. UroGen Pharma's overall GF Score™ is 60/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current Days Inventory is 409.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (FRA:UR8) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of €33.93 is trading 89.8% above its estimated GF Value™ of €17.88.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for FRA:UR8:
Days Inventory: 409.71 (70% above median its 10-year median of 240.50)
GF Value™: €17.88 vs. price of €33.93 (89.8% above fair value)
Industry Position: 123.6% above the Biotechnology median (#443 of 638)
No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
60GF Score
Get the complete analysis for FRA:UR8
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UR8 has been successfully added to your 
